Septerna Reports Positive Phase 1 Data for SEP-631, Advancing to Phase 2b for Chronic Spontaneous Urticaria
SEPN has more than doubled off its 52-week low of $4.66.
Summary
Septerna announced positive Phase 1 clinical trial results for its lead candidate, SEP-631, demonstrating favorable safety, pharmacokinetics, and clinical proof-of-mechanism. The company plans to advance SEP-631 into a Phase 2b trial for chronic spontaneous urticaria in the second half of 2026.
Key Events · Product Development and Regulatory · SEPN
-
Positive Phase 1 Results for SEP-631
Septerna announced positive data from its Phase 1 clinical trial for SEP-631, an oral MRGPRX2 NAM for mast cell-driven diseases. The trial assessed safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) activity in healthy volunteers.
-
Favorable Safety and Pharmacokinetics
SEP-631 was well-tolerated across all doses, with an adverse event profile comparable to placebo and no severe or serious adverse events. It demonstrated a PK profile supporting convenient once-daily oral dosing with an approximate 24-hour half-life and no clinically meaningful food effect.
-
Clinical Proof-of-Mechanism Achieved
The drug produced robust, dose-dependent suppression of icatibant-induced skin wheal formation, an established measure of mast cell activation, with complete inhibition observed at doses as low as 10 mg once daily. This provides clinical proof-of-mechanism for MRGPRX2 pathway inhibition.
-
Phase 2b Trial Planned for H2 2026
Based on these results, Septerna plans to initiate a Phase 2b clinical trial of SEP-631 in chronic spontaneous urticaria (CSU) in the second half of 2026, following the completion of ongoing long-term toxicology studies. The company is also evaluating other mast cell-driven indications.
Analysis · SEPN · Life Sciences
Septerna's announcement of positive Phase 1 results for SEP-631 is a significant de-risking event for the clinical-stage biotechnology company. The robust safety profile, favorable pharmacokinetics, and clear clinical proof-of-mechanism validate the drug candidate and the company's Native Complex Platform. The outlined plan to initiate a Phase 2b trial in chronic spontaneous urticaria (CSU) in the second half of 2026 provides a clear development pathway for a potentially differentiated oral treatment in a disease with high unmet medical need. This progress could significantly enhance investor confidence in Septerna's pipeline and technology.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 35.8% of the 1190 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.45%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SEPN was trading at $28.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $4.66 to $32.63. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.